Premium
Proteomics as a tool for assessment of therapeutics in transfusion medicine: evaluation of prothrombin complex concentrates
Author(s) -
Brigulla Matthias,
Thiele Thomas,
Scharf Christian,
BreitnerRuddock Susanne,
Venz Simone,
Völker Uwe,
Greinacher Andreas
Publication year - 2006
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1111/j.1537-2995.2006.00732.x
Subject(s) - transfusion medicine , medicine , intensive care medicine , proteomics , blood transfusion , immunology , biology , biochemistry , gene
BACKGROUND: Proteomic technologies are evolving tools to analyze complex protein patterns that to date have been rarely applied to transfusion medicine. The analysis of prothrombin complex concentrates (PCCs) was used as a model to evaluate to what extent these technologies can detect differences in blood‐derived therapeutics beyond that of standard quality control. STUDY DESIGN AND METHODS: Three PCCs (two batches each) were individually analyzed for differences in protein content by functional assays, two‐dimensional gel electrophoresis, and mass spectrometry. The results were compared to a pool of 72 normal plasma samples. RESULTS: A highly complex protein pattern was found that varied considerably among the three PCCs: 192 spots comprising 40 different proteins were identified. Factor (F) IX activities of the three PCCs were comparable, but their F IX protein contents differed considerably. Many proteins were present in multiple spots (e.g. FII, FX, protein C, vitronectin), indicating a high degree of posttranslational modifications. In comparison with untreated pooled plasma, PCCs displayed several low‐molecular‐weight variants of proteins that likely constitute potential degradation products. CONCLUSION: Proteomic technologies allow the identification of potentially modified proteins in clotting factor concentrates, indicating that they could become a useful tool for transfusion medicine to assess the impact of processing on the integrity of blood‐derived therapeutics.